首页> 外文期刊>Contemporary Clinical Trials Communications >A prospective development study of software-guided radio-frequency ablation of primary and secondary liver tumors: Clinical intervention modelling, planning and proof for ablation cancer treatment (ClinicIMPPACT)
【24h】

A prospective development study of software-guided radio-frequency ablation of primary and secondary liver tumors: Clinical intervention modelling, planning and proof for ablation cancer treatment (ClinicIMPPACT)

机译:原发性和继发性肝肿瘤的软件指导射频消融的前瞻性研究:消融癌治疗的临床干预模型,规划和证明(ClinicIMPPACT)

获取原文
           

摘要

Introduction Radio-frequency ablation (RFA) is a promising minimal-invasive treatment option for early liver cancer, however monitoring or predicting the size of the resulting tissue necrosis during the RFA-procedure is a challenging task, potentially resulting in a significant rate of under- or over treatments. Currently there is no reliable lesion size prediction method commercially available. Objectives ClinicIMPPACT is designed as multicenter-, prospective-, non-randomized clinical trial to evaluate the accuracy and efficiency of innovative planning and simulation software. 60 patients with early liver cancer will be included at four European clinical institutions and treated with the same RFA system. The preinterventional imaging datasets will be used for computational planning of the RFA treatment. All ablations will be simulated simultaneously to the actual RFA procedure, using the software environment developed in this project. The primary outcome measure is the comparison of the simulated ablation zones with the true lesions shown in follow-up imaging after one month, to assess accuracy of the lesion prediction. Discussion This unique multicenter clinical trial aims at the clinical integration of a dedicated software solution to accurately predict lesion size and shape after radiofrequency ablation of liver tumors. Accelerated and optimized workflow integration, and real-time intraoperative image processing, as well as inclusion of patient specific information, e.g. organ perfusion and registration of the real RFA needle position might make the introduced software a powerful tool for interventional radiologists to optimize patient outcomes.
机译:引言射频消融(RFA)是早期肝癌的一种有希望的微创治疗方案,但是在RFA手术过程中监测或预测由此产生的组织坏死的大小是一项艰巨的任务,可能导致显着的肿瘤坏死率下降。 -或过度治疗。当前,没有可商购的可靠的病变尺寸预测方法。目的ClinicIMPPACT设计为多中心,前瞻性,非随机的临床试验,旨在评估创新计划和模拟软件的准确性和效率。 60例早期肝癌患者将被纳入四个欧洲临床机构,并接受相同的RFA系统治疗。介入前成像数据集将用于RFA治疗的计算计划。使用本项目中开发的软件环境,所有消融将与实际的RFA程序同时进行模拟。主要结果指标是将模拟消融区与一个月后随访影像中显示的真实病变进行比较,以评估病变预测的准确性。讨论这项独特的多中心临床试验旨在将专用软件解决方案进行临床集成,以准确预测射频消融肝肿瘤后的病变大小和形状。加速和优化的工作流程集成,实时术中图像处理以及包括患者特定信息的信息,例如器官灌注和RFA实际针头位置的记录可能会使所引入的软件成为介入放射科医生优化患者结果的强大工具。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号